TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $599.76M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 28.54B 722M Sep/2025
Alaunos Therapeutics USD 2.68M 1.05M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
Ardelyx USD 367.98M 16.42M Sep/2025
Arrowhead Research USD 950.64M 3.72M Sep/2025
Bayer EUR 32.88B 873M Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
Corcept Therapeutics USD 541.13M 98.02M Sep/2025
Dynavax Technologies USD 814.33M 28.62M Sep/2025
Gilead Sciences USD 18.84B 4.12B Sep/2025
J&J USD 54.61B 113M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Regeneron Pharmaceuticals USD 17.98B 1.12B Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025